Organon OGN
NYSE OGN
$13.72 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Organon (OGN) Net Income towards Common Stockholders (2020 - 2026)

Updated

Organon (OGN) posted Net Income towards Common Stockholders of $108 million for Q2 2026, down 25.5% from $145 million a year earlier and down 26.0% from the prior quarter.

Analysis

Organon (OGN) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Net Income towards Common Stockholders at Organon was $209 million, down 70.1% year-over-year; for FY2025, it was $187 million, down 78.4% from FY2024.

  • Annual Net Income towards Common Stockholders shows a five-year compound annual growth rate of -38.7% (FY2020 to FY2025).
  • In prior years, Organon's Net Income towards Common Stockholders was $864 million in FY2024 (-15.5%), $1.02 billion in FY2023 (+11.6%), $917 million in FY2022 (-32.1%) and $1.35 billion in FY2021 (-37.5%).
  • Quarterly Net Income towards Common Stockholders has run from a low of -$205 million in Q4 2025 to a high of $546 million in Q4 2023 over five years.
  • On a year-over-year basis, Net Income towards Common Stockholders increased in two of the last seven quarters, with growth averaging 49.1%.
  • The strongest year-over-year quarter for Net Income towards Common Stockholders in the past five years was Q3 2024, with growth of 519.0%; the weakest was Q4 2024, with a decline of 80.0%.
  • According to Business Quant data, Net Income towards Common Stockholders for the three prior quarters was $146 million (Q1 2026), -$205 million (Q4 2025) and $160 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 5.53 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 3.61 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.89 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -10.50 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -248.00 Mn
10 Organon 3.60 Bn 109.00 Mn 847.00 Mn 108.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 108.00 Mn
Mar 31, 2026 146.00 Mn
Dec 31, 2025 -205.00 Mn
Sep 30, 2025 160.00 Mn
Jun 30, 2025 145.00 Mn
Mar 31, 2025 87.00 Mn
Dec 31, 2024 109.00 Mn
Sep 30, 2024 359.00 Mn
Jun 30, 2024 195.00 Mn
Mar 31, 2024 201.00 Mn
Dec 31, 2023 546.00 Mn
Sep 30, 2023 58.00 Mn
Jun 30, 2023 242.00 Mn
Mar 31, 2023 177.00 Mn
Dec 31, 2022 108.00 Mn
Sep 30, 2022 227.00 Mn
Jun 30, 2022 234.00 Mn
Mar 31, 2022 348.00 Mn
Dec 31, 2021 202.00 Mn
Sep 30, 2021 323.00 Mn
API Access

Organon Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=OGN&period=max&api_key=YOUR_API_KEY